These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 6204531)

  • 1. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.
    Bast RC; Klug TL; Schaetzl E; Lavin P; Niloff JM; Greber TF; Zurawski VR; Knapp RC
    Am J Obstet Gynecol; 1984 Jul; 149(5):553-9. PubMed ID: 6204531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
    Bast RC; Klug TL; St John E; Jenison E; Niloff JM; Lazarus H; Berkowitz RS; Leavitt T; Griffiths CT; Parker L; Zurawski VR; Knapp RC
    N Engl J Med; 1983 Oct; 309(15):883-7. PubMed ID: 6310399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Ca 125 as tumor marker in ovarian carcinoma.
    Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
    Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer.
    Yuan CC; Ng HT; Tsai LC; Jeng FS; Yeh SH; Tsai YC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):190-7. PubMed ID: 3480793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoradiometric assay of CA 125 in effusions. Comparison with carcinoembryonic antigen.
    Pinto MM; Bernstein LH; Brogan DA; Criscuolo E
    Cancer; 1987 Jan; 59(2):218-22. PubMed ID: 3467816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
    Wu JT; Miya T; Knight JA; Knight DP
    Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
    Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C
    Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
    Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor markers in gynecologic diseases].
    Geyer H; Kleine W
    Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
    Hayes DF; Zurawski VR; Kufe DW
    J Clin Oncol; 1986 Oct; 4(10):1542-50. PubMed ID: 2428949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies.
    Charpin C; Bhan AK; Zurawski VR; Scully RE
    Int J Gynecol Pathol; 1982; 1(3):231-45. PubMed ID: 6193072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
    Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H; Teshima K; Noda K
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of measurement of a carbohydrate antigenic determinant 19-9 (CA 19-9) for monitoring colorectal cancer patients.
    Tomoda H; Furusawa M
    Jpn J Surg; 1986 Jan; 16(1):73-5. PubMed ID: 2421035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.
    Sekine H; Hayes DF; Ohno T; Keefe KA; Schaetzl E; Bast RC; Knapp R; Kufe DW
    J Clin Oncol; 1985 Oct; 3(10):1355-63. PubMed ID: 2413181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
    Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
    Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
    Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
    Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
    Negishi Y; Furukawa T; Oka T; Sakamoto M; Hirata T; Okabe K; Matayoshi K; Akiya K; Soma H
    Gynecol Obstet Invest; 1987; 23(3):200-7. PubMed ID: 3474196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.